Tests radiation before lung transplant in people with lung cancer
Tests radiation given before lung transplant in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Toronto General Hospital, University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Marc de Perrot
- Trial code
- NCT04782752
- Record updated
- 10 September 2026
- Original description
This is a prospective phase I study to determine the safety and feasibility of non-ablative oligofractionated radiation therapy (NORT) before lung transplantation for patients with underlying pulmonary malignancy. We hypothesize that heterogeneous dose distributions could generate a vaccination effect against the tumor by creating anti-tumoral immune response in the body and these patients may be immunized against their tumor which could reduce the risk of cancer recurrence after transplantation despite the anti-rejection medications required for the transplantation.Read full original descriptionShow less
Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination
This is a prospective phase I study to determine the safety and feasibility of non-ablative oligofractionated radiation therapy (NORT) before lung transplantation for patients with underlying pulmonary malignancy. We hypothesize that heterogeneous dose distributions could generate a vaccination effect against the tumor by creating anti-tumoral immune response in the body and these patients may be immunized against their tumor which could reduce the risk of cancer recurrence after transplantation despite the anti-rejection medications required for the transplantation.
Inclusion: Age ≥ 18; Patients with end-stage lung disease and suspected stage I primary lung cancer based on CT and PET scan not accessible to curative treatment, including surgery and ablative SBRT; Patients with multifocal pulmonary malignancy, including multifocal lung adenocarcinoma, not accessible to curative treatment, including surgery and ablative SBRT; Patients with isolated metastases in one or both lungs after complete resection of the primary tumor in the absence of other sites of metastatic disease, not accessible to curative treatment, including surgery and ablative SBRT; Meet eligibility criteria for lung transplantation with the exception of the underlying malignancy; Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study.
Exclusion: Previous thoracic radiation resulting in significant mediastinal or chest wall overlap precluding re-irradiation; Failure to provide informed consent; Any other medical condition that, in the opinion of the multidisciplinary team, may interfere with the subject's participation or compliance with the treatment; Age < 18; Mediastinal nodes metastasis demonstrated on EBUS-TBNA; Distant metastasis demonstrated on PET scan or brain imaging.